High-priority targets include established therapeutic genes such as IGF1, for which mecasermin represents an existing FDA-approved treatment, and GRIA1/GRIN2A, which are targeted by memantine and other glutamate receptor modulators currently used in Alzheimer’s disease management. The gene discussed is IGF1; the disease is early-onset autosomal dominant Alzheimer disease.